Skip to main content
. Author manuscript; available in PMC: 2013 Oct 1.
Published in final edited form as: Arthritis Rheum. 2012 Oct;64(10):3111–3118. doi: 10.1002/art.34560

Figure 1.

Figure 1

RTX added to PBMC in 10% serum results in rapid loss of CD19 as measured by flow cytometry. A, Representative dot plot of untreated and RTX treated lymphocytes as determined by forward and side scatter properties. B, Bar graph representing mean percent positive CD19 cells without and with RTX treatment (p<0.0001) and change in mean fluorescence intensity (MFI) (p<0.0001, n=37). C, RTX promotes depletion of CD19 in a dose-dependent manner with an incubation of 30 minutes (n=4). D, CD19 depletion occurs as rapidly as 5 minutes at RTX dose of 10 µg/ml (n=5). Error bars represent standard error of the mean.